Compare HCC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCC | TNGX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.1B |
| IPO Year | 2017 | 2020 |
| Metric | HCC | TNGX |
|---|---|---|
| Price | $82.23 | $30.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $95.29 | $21.78 |
| AVG Volume (30 Days) | 620.3K | ★ 4.5M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $1,310,043,000.00 | $62,384,000.00 |
| Revenue This Year | $59.95 | N/A |
| Revenue Next Year | $8.77 | N/A |
| P/E Ratio | $60.03 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $49.07 | $5.60 |
| 52 Week High | $110.39 | $34.39 |
| Indicator | HCC | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 54.32 |
| Support Level | $77.26 | $28.13 |
| Resistance Level | $92.19 | $33.96 |
| Average True Range (ATR) | 3.18 | 1.89 |
| MACD | 0.34 | -0.33 |
| Stochastic Oscillator | 59.42 | 37.88 |
Warrior Met Coal Inc produces and exports met or steelmaking coal, which is used as a component for steel production by metal manufacturers in Europe, South America, and Asia. The company is involved in longwall mining operations in its underground mines based in Alabama, Mine No. 4, Mine No. 7, and Blue Creek. Additionally, its natural gas operations remove and sell natural gas from owned and leased coal seams by reducing natural gas levels in its mines. The company generates revenue mainly through the production of steelmaking coal for sale to the steel industry. Geographically, the firm generates maximum revenue from its customers in Asia, followed by Europe, South America, and the United States.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.